JPH0128005B2 - - Google Patents
Info
- Publication number
- JPH0128005B2 JPH0128005B2 JP55166478A JP16647880A JPH0128005B2 JP H0128005 B2 JPH0128005 B2 JP H0128005B2 JP 55166478 A JP55166478 A JP 55166478A JP 16647880 A JP16647880 A JP 16647880A JP H0128005 B2 JPH0128005 B2 JP H0128005B2
- Authority
- JP
- Japan
- Prior art keywords
- parts
- weight
- volume
- oleic acid
- ethyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 21
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 21
- -1 poly(ethylene glycol) Polymers 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 17
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 229940093471 ethyl oleate Drugs 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 claims description 2
- BIYCJLNXUANNTD-UHFFFAOYSA-N 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-4,6-diamine Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC=NC=2N)N)=C1 BIYCJLNXUANNTD-UHFFFAOYSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 14
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 14
- 229960001082 trimethoprim Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- 229940102223 injectable solution Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KEWIUFDNNIFKJK-KVVVOXFISA-N (z)-octadec-9-enoic acid;hydrate Chemical compound O.CCCCCCCC\C=C/CCCCCCCC(O)=O KEWIUFDNNIFKJK-KVVVOXFISA-N 0.000 description 1
- XZHSSCMFBOTKMO-UHFFFAOYSA-N 2-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine Chemical compound COC1=C(OC)C(OC)=CC(CC=2N=CC=CN=2)=C1 XZHSSCMFBOTKMO-UHFFFAOYSA-N 0.000 description 1
- QFSUYQMKGGVNLS-UHFFFAOYSA-N 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine Chemical compound COC1=C(OC)C(OC)=CC(CC=2C=NC=NC=2)=C1 QFSUYQMKGGVNLS-UHFFFAOYSA-N 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- RZHBMYQXKIDANM-UHFFFAOYSA-N dioctyl butanedioate;sodium Chemical compound [Na].CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC RZHBMYQXKIDANM-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 229940099427 potassium bisulfite Drugs 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940072176 sulfonamides and trimethoprim antibacterials for systemic use Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU79EE2710A HU180740B (en) | 1979-11-27 | 1979-11-27 | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5687517A JPS5687517A (en) | 1981-07-16 |
| JPH0128005B2 true JPH0128005B2 (pt) | 1989-05-31 |
Family
ID=10995877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16647880A Granted JPS5687517A (en) | 1979-11-27 | 1980-11-26 | Medicinal composition for durable effect type injection |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5687517A (pt) |
| AT (1) | AT371339B (pt) |
| BE (1) | BE886310A (pt) |
| DD (1) | DD154802A5 (pt) |
| DE (1) | DE3044753A1 (pt) |
| FR (1) | FR2469924A1 (pt) |
| GB (1) | GB2066068B (pt) |
| HU (1) | HU180740B (pt) |
| IT (1) | IT1149268B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU210693B (en) | 1991-10-11 | 1995-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions for injections without tissue damages, containing sulfamethoxazol and trimetoprime |
| CN100376893C (zh) * | 2006-08-18 | 2008-03-26 | 中国水产科学研究院黄海水产研究所 | 同时测定鱼肉中磺胺甲唑、乙酰化磺胺甲唑及甲氧苄啶的液相色谱法 |
| CN113952296B (zh) * | 2021-11-15 | 2023-10-13 | 山东新华制药股份有限公司 | 一种复方磺胺甲噁唑注射液的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH544053A (de) * | 1966-05-09 | 1973-11-15 | Hoffmann La Roche | Verfahren zur Herstellung von Sulfonamidderivaten |
| US3985876A (en) * | 1973-01-05 | 1976-10-12 | Burroughs Wellcome Co. | Chemotherapeutic solutions containing a sulphur and a salt of a 2,4-diamino-5-benzylpyrimidine |
| GB1469521A (en) * | 1973-01-05 | 1977-04-06 | Wellcome Found | Antimicrobial preparations |
| DK136934B (da) * | 1976-02-06 | 1977-12-19 | Rosco As | Fremgangsmåde til fremstilling af en klar, stabil, injicerbar opløsning indeholdende et sulfonamid og en potentiator. |
| DE2631779A1 (de) * | 1976-07-15 | 1978-01-19 | Basf Ag | Sulfonamid-trimethoprim-loesungen |
-
1979
- 1979-11-27 HU HU79EE2710A patent/HU180740B/hu not_active IP Right Cessation
-
1980
- 1980-11-24 FR FR8024891A patent/FR2469924A1/fr active Granted
- 1980-11-24 BE BE1/10048A patent/BE886310A/fr not_active IP Right Cessation
- 1980-11-26 AT AT0577380A patent/AT371339B/de not_active IP Right Cessation
- 1980-11-26 GB GB8037932A patent/GB2066068B/en not_active Expired
- 1980-11-26 DD DD80225492A patent/DD154802A5/de not_active IP Right Cessation
- 1980-11-26 JP JP16647880A patent/JPS5687517A/ja active Granted
- 1980-11-26 IT IT26237/80A patent/IT1149268B/it active
- 1980-11-27 DE DE19803044753 patent/DE3044753A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2469924A1 (fr) | 1981-05-29 |
| JPS5687517A (en) | 1981-07-16 |
| IT1149268B (it) | 1986-12-03 |
| BE886310A (fr) | 1981-05-25 |
| GB2066068A (en) | 1981-07-08 |
| DE3044753C2 (pt) | 1990-05-10 |
| DE3044753A1 (de) | 1981-06-19 |
| FR2469924B1 (pt) | 1984-06-29 |
| DD154802A5 (de) | 1982-04-21 |
| ATA577380A (de) | 1982-11-15 |
| AT371339B (de) | 1983-06-27 |
| HU180740B (en) | 1983-04-29 |
| IT8026227A0 (it) | 1980-11-26 |
| GB2066068B (en) | 1983-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0546018B1 (en) | Pharmaceutical composition of florfenicol | |
| ES2241198T3 (es) | Preparacion aplicable percutaneamente que contiene hidrocloruro de donepezil. | |
| ES2326426T3 (es) | Formulaciones pastosas que comprenden silice. | |
| RU2126262C1 (ru) | Фармацевтическая композиция | |
| RU2694368C2 (ru) | Твердые фармацевтические композиции, содержащие производные биоптерина, и способы применения таких композиций | |
| BRPI0613731A2 (pt) | composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta | |
| CA1290690C (en) | Method of reducing the swelling or pain associated with antibiotics compositions | |
| JPH03169812A (ja) | トリアセチンを含む活性持続性注射用処方剤 | |
| JPS647046B2 (pt) | ||
| EA013616B1 (ru) | Инъекционные препараты диклофенака и его фармацевтически приемлемых солей | |
| CN112823787B (zh) | 一种含有美洛昔康的注射液及其制备方法 | |
| JPH10502628A (ja) | 長時間作用オキシテトラサイクリン組成物 | |
| JPS605567B2 (ja) | オキシテトラサイクリンの調合液 | |
| JPH0128005B2 (pt) | ||
| WO2021033145A1 (en) | Novel injectable formulations of artesunate | |
| JPH11513365A (ja) | １，２，４−ベンゾトリアジンオキシドの経口ゲルカプセル製剤 | |
| JP2007045788A (ja) | グリチルリチン酸高濃度水溶液の調製法 | |
| EP0238207B1 (en) | Bactericidal mixtures | |
| NO863082L (no) | Preparat for intramuskulaer injeksjon av legemidler, vitaminer eller vaksiner. | |
| RU2103997C1 (ru) | Лекарственное средство для лечения заболеваний животных микробной этиологии, способ лечения желудочно-кишечных заболеваний животных микробной этиологии и способы лечения гинекологических заболеваний коров микробной этиологии | |
| KR102213669B1 (ko) | 카페인 가용화 조성물 | |
| RU2182830C1 (ru) | Таблетированная форма рекомбинантного человеческого эритропоэтина | |
| RU2118156C1 (ru) | Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для инъекций | |
| SK74699A3 (en) | An oil composition of dihydropolyprenols | |
| RU2007152C1 (ru) | Офтальмологическое средство и способ его получения |